|
Forxiga receives positive EU CHMP opinion for the treatment of adults with type-1 diabetes
|
04 February 2019 |
|
AstraZeneca announces organisational changes
|
07 January 2019 |
|
Lynparza meets primary endpoint in Phase III SOLO-3 trial for the treatment of relapsed BRCA-mutated advanced ovarian cancer
|
27 December 2018 |
|
AstraZeneca and Cancer Research UK launch Functional Genomics Centre to accelerate the discovery of new medicines
|
10 December 2018 |
|
AstraZeneca to divest US Synagis rights to Sobi
|
13 November 2018 |
|
Divestment of rights to Alvesco, Omnaris and Zetonna to Covis Pharma
|
06 November 2018 |
|
Agreement with Grünenthal for rights to Nexium in Europe and Vimovo worldwide (ex-US)
|
30 October 2018 |
|
AstraZeneca strengthens and expands oncology development and commercialisation collaboration with Innate Pharma
|
24 October 2018 |
|
US FDA grants Lynparza Orphan Drug Designation for pancreatic cancer
|
18 October 2018 |
|
Imfinzi is the first immunotherapy to demonstrate significant overall survival benefit in unresectable, Stage III lung cancer
|
25 September 2018 |